UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
x Quarterly Report Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
for the Period Ended March 31, 2001.
or
¨ Transition Report Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934
for the Transition Period From _____________
to __________________.
Commission file number 0-27436
Titan Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
| Delaware
|
94-3171940
|
| (State or Other Jurisdiction of | (I.R.S. Employer |
| Incorporation or Organization) | Identification No.) |
| 400 Oyster Point
Blvd., Suite 505, South San Francisco, California 94080 |
| (Address of Principal Executive Offices including zip code) |
| (650) 244-4990 |
| (Registrant's Telephone Number, Including Area Code) |
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
There were 27,603,844 of the Registrant’s Common Stock issued and outstanding on May 7, 2001.
Titan Pharmaceuticals, Inc.
Index to Form 10-Q
Part I. Financial Information
TITAN
PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE
SHEETS
(in thousands)
| March 31, | December 31, | |
| 2001 |
2000 |
|
| (unaudited) | (Note A) | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $9,774 | $20,300 |
| Marketable securities | 104,647 | 97,223 |
| Prepaid expenses, receivables, and other current assets | 854
|
326
|
| Total current assets | 115,275 | 117,849 |
| Furniture and equipment, net | 591
|
593
|
| $115,866
|
$118,442
|
|
| Liabilities and Stockholders' Equity | ||
| Current liabilities | ||
| Accounts payable | $1,048 | $1,304 |
| Accrued clinical trials expenses | 934 | 432 |
| Other accrued liabilities | 638
|
727
|
| Total current liabilities | 2,620 | 2,463 |
| Minority interest - Series B preferred stock of Ingenex, Inc. | 1,241 | 1,241 |
| Stockholders' equity | ||
| Common stock, at amounts paid in | 191,385 | 190,763 |
| Additional paid-in capital | 8,595 | 8,744 |
| Deferred compensation | (1,098) | (1,254) |
| Accumulated deficit | (88,725) | (84,206) |
| Accumulated other comprehensive income | 1,848
|
691
|
| Total stockholders' equity | 112,005
|
114,738
|
| $115,866
|
$118,442
|
|
| Note A: The balance sheet has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements presentation. | ||
See Notes to Condensed Consolidated Financial Statements
TITAN
PHARMACEUTICALS, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share amount)
| Three Months Ended
March 31, |
||
| 2001 |
2000 |
|
| Revenue: | ||
| Contract revenue | $321 | $280 |
| Grant revenue | 259
|
55
|
| Total revenue | 580 | 335 |
| Operating expenses: | ||
| Research and development | 4,999 | 4,045 |
| General and administrative | 1,584
|
857
|
| Total operating expenses | 6,583
|
4,902
|
| Loss from operations | (6,003) | (4,567) |
| Other income (expense): | ||
| Interest income, net | 1,535 | 938 |
| Other expense | (51)
|
(19)
|
| Other income, net | 1,484
|
919
|
| Net loss | $(4,519)
|
$(3,648)
|
| Basic and diluted net loss per share | $(0.16)
|
$(0.15)
|
| Weighted average shares used in computing basic and diluted net loss per share | 27,468
|
23,873
|
See Notes to Condensed Consolidated Financial Statements
TITAN
PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
| Three Months Ended
March 31, |
||
| 2001 |
2000 |
|
| Cash flows from operating activities: | ||
| Net loss | $(4,519) | $(3,648) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 63 | 84 |
| Non-cash compensation related to stock options | 6 | 110 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, receivables, and other current assets | (528) | (983) |
| Accounts payable and other accrued liabilities | 157 | 115 |
| Unearned contract revenue | -
|
265
|
| Net cash used in operating activities | (4,821)
|
(4,057)
|
| Cash flows from investing activities: | ||
| Purchases of furniture and equipment, net | (60) | (83) |
| Purchases of marketable securities | (26,467) | (79,752) |
| Proceeds from sales of marketable securities | 20,200
|
2,000
|
| Net cash used in investing activities | (6,327)
|
(77,835)
|
| Cash flows from financing activities: | ||
| Issuance of common stock, net | 622
|
41,665
|
| Net cash provided by financing activities | 622
|
41,665
|
| Net decrease in cash and cash equivalents | (10,526) | (40,227) |
| Cash and cash equivalents at beginning of period | 20,300
|
46,454
|
| Cash and cash equivalents at end of period | 9,774 | 6,227 |
| Marketable securities at end of period | 104,647
|
77,638
|
| Cash, cash equivalents and marketable securities at end of period | $114,421
|
$83,865
|
See Notes to Condensed Consolidated Financial Statements
TITAN
PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. Organization and Summary of Significant Accounting Policies
The Company
We are a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. We conduct a minor portion of our operations through our two subsidiaries: Ingenex, Inc. and ProNeura, Inc. Ingenex is engaged in the development of gene-based therapeutics for the treatment of cancer. At March 31, 2001, we owned 81% of Ingenex, assuming the conversion of all preferred stock to common stock. ProNeura is engaged in the development of cost effective, long-term treatment solutions to neurologic and psychiatric disorders through an implantable drug delivery system. At March 31, 2001, we owned 79% of ProNeura. We operate in one business segment, the development of biopharmaceutical products.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements include the accounts of Titan and its subsidiaries after elimination of all significant intercompany accounts and transactions. These financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March 31, 2001 are not necessarily indicative of the results that may be expected for the year ending December 31, 2001.
These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Titan Pharmaceuticals, Inc. annual report on Form 10-K for the year ended December 31, 2000.
Revenue Recognition
Revenue under collaborative agreements is recorded when earned as defined under the terms of the respective agreements and collectibility is reasonably assured. Payments for our research and development efforts under contractual arrangements are recognized ratably over the period in which the related work is performed. Nonrefundable license fees, with respect to which we have no future performance obligations, are recognized upon receipt. Government grants, which support our research efforts in specific projects, generally provide for reimbursement of approved costs as defined in the grant documents. Grant revenues are recognized when subsidized project costs are incurred.
2. Net Loss Per Share
We calculate basic net loss per share using the weighted average common shares outstanding for the period. Had we been in a net income position, shares used in calculating diluted earnings per share for the periods ended March 31, 2001 and 2000 would have included the effect of an additional 3,838,918 and 3,599,111 shares, respectively, related to our convertible preferred stock, options and warrants.
3. Comprehensive Income (Loss)
Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). The only component of other comprehensive income (loss) is unrealized gains and losses from our marketable securities. Comprehensive loss for the three months ended March 31, 2001 and 2000 were $3.4 million and $3.8 million, respectively.
4. Recent Accounting Pronouncement
In June 1998, the Financial Accounting Standards Board issued SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities" (SFAS 133), which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities. We adopted SFAS 133 on January 1, 2001. Because we do not hold any derivative instruments and do not engage in hedging activities, the adoption of SFAS 133 did not have an impact on our financial position or results of operations.
5. Loan to Officer
In February 2001, we provided a loan of approximately $0.4 million to a vice president executive officer to finance certain federal and state income tax liabilities incurred by the executive in connection with the exercise of stock options. The loan bears a fixed interest rate of 8.50% per year and is due and payable in August 2001. As of March 31, 2001, the amount outstanding on the loan was $0.4 million.
6. Subsequent Event
In April 2001, we entered into an agreement with Novartis Pharma AG for the development and commercialization of ZomarilÔ in Japan. ZomarilÔ is a novel antipsychotic agent that is currently completing a world-wide Phase III development program. This new agreement expands upon Titan and Novartis’ previously executed and ongoing agreement for world-wide development, manufacturing, and marketing of ZomarilÔ outside Japan. Under the new agreement, in exchange for rights to ZomarilÔ in Japan, Titan received a $2.5 million license fee in May 2001, and will receive future payments contingent upon the achievement of certain regulatory milestones as well as royalties on product sales in Japan consistent with the previous agreement.
Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations
The following discussion contains certain forward–looking statements, within the meaning of the "safe harbor" provisions of the Private Securities Reform Act of 1995, the attainment of which involves various risks and uncertainties. Forward–looking statements may be identified by the use of forward–looking terminology such as "may," "will," "expect," "believe," "estimate," "anticipate," "continue," or similar terms, variations of those terms or the negative of those terms. Our actual results may differ materially from those described in these forward–looking statements due to, among other factors, the results of ongoing research and development activities and pre–clinical testing, the results of clinical trials and the availability of additional financing through corporate partnering arrangements or otherwise. Additional factors include our ability to protect our patents and proprietary rights, ability to comply with extensive government regulations, and other factors and risks detailed under the caption "Risk Factors" in the Company's 2000 Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Stockholders and prospective investors in the Company should carefully consider these risk factors. The Company disclaims any obligation to update these statements for subsequent events.
Spheramine®, CeaVac®, TriAb®, TriGem®, Pivanex® and CCM™ are trademarks of Titan Pharmaceuticals, Inc. Zomaril™ is a trademark of Novartis Pharma AG.
Overview
We are a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. Our product development programs focus on large pharmaceutical markets with significant unmet medical needs and commercial potential. We currently have nine products in development, seven of which are in clinical development, with two products in late stage human trials for safety and efficacy, known as Phase III clinical trials. We have five products in preliminary trials for human safety and efficacy, known as Phase I/II and Phase II clinical trials. In addition to these programs, we have two products in preclinical development. We are independently developing our product candidates and also utilizing strategic partnerships, including collaborations with Novartis Pharma AG and Schering AG, as well as collaborations with several government-sponsored clinical cooperative groups. These collaborations help fund product development and enable us to retain significant economic interest in our products.
Our Clinical Development Programs
The following table sets forth our products in clinical development:
| Product |
Indication(s) |
Status |
Marketing
Rights |
| Zomaril | Schizophrenia, psychosis | Phase III | Novartis Pharma AG |
| Spheramine | Parkinson’s disease | Phase I/II | Schering AG |
| CeaVac | Colorectal, gastrointestinal and pancreatic cancer | Phase III (colorectal cancer) | Titan Pharmaceuticals |
| TriAb | Breast and ovarian cancer | Phase II (breast cancer) | Titan Pharmaceuticals |
| TriGem | Small cell lung cancer, melanoma | Phase II (melanoma) | Titan Pharmaceuticals |
| Pivanex | Non-small cell lung cancer | Phase II | Titan Pharmaceuticals |
| Gallium Maltolate | Myeloma, prostate and bladder cancer, lymphoma, HIV | Phase I/II (prostate cancer and multiple myeloma) | Titan Pharmaceuticals |
Results of Operations
Revenues for the first quarter 2001 were approximately $600,000 compared to $300,000 for the same quarter in 2000, an increase of approximately $300,000. The increase in revenue was primarily due to an SBIR grant from the National Institutes of Health in support of the development of Spheramine, our novel treatment for Parkinson's disease.
Research and development expenses for the first quarter 2001 were $5.0 million, compared to $4.0 million for the same quarter in 2000. The increase in research and development expenditures resulted primarily from ongoing accrual of patients in the randomized, placebo-controlled Phase III clinical study of CeaVac in Dukes D colorectal cancer, expenses associated with the Phase I/II clinical trial with Spheramine, and increased development activities to advance our newly acquired product candidate, Gallium Maltolate, as well as our other product candidates.
General and administrative expenses for the first quarter 2001 were $1.6 million compared to $0.9 million for the same quarter in 2000. The increase was in support of our expanded clinical operations, infrastructure development and certain stock option related non-cash compensation charges.
Other income, net, for the first quarter 2001 was $1.5 million compared to $0.9 million in the first quarter 2000. The increase, primarily in interest income, was a result of our significantly larger cash and marketable securities position.
As a result of the foregoing, we had a net loss for the first quarter 2001 of $4.5 million, or $0.16 per share, compared to $3.6 million, or $0.15 per share, for the same quarter in 2000.
Liquidity and Capital Resources
We have funded our operations since inception primarily through our initial public offering and private placements of our securities, as well as proceeds from warrant and option exercises, corporate licensing and collaborative agreements, and government sponsored research grants. At March 31, 2001, we had $114.4 million of cash, cash equivalents, and marketable securities.
In November 2000, we completed a private placement of 1.2 million shares of our common stock for net proceeds of approximately $40.9 million, after deducting fees and commissions and other expenses of the offering.
In March 2000, we completed a private placement of 1.2 million shares of our common stock for net proceeds of approximately $38.8 million, after deducting fees and commissions and other expenses of the offering.
Our operating activities used $4.8 million and $4.1 million of cash in the first quarter 2001 and 2000, respectively. Uses of cash in operating activities were primarily to fund product development programs and administrative expenses. We have entered into various agreements with research institutions, universities, and other entities for the performance of research and development activities and for the acquisition of licenses related to those activities. The aggregate commitments we have under these agreements, including minimum license payments, for the next 12 months is approximately $0.8 million. Certain of the licenses require us to pay royalties on future product sales, if any. In addition, in order to maintain license and other rights while products are under development, we must comply with customary licensee obligations, including the payment of patent related costs and diligent efforts in product development.
We expect to continue to incur substantial additional operating losses from costs related to continuation and expansion of product and technology development, clinical trials, and administrative activities. We believe that we currently have sufficient working capital to sustain our planned operations through 2005.
Item 3. Quantitative and Qualitative Disclosures About Market
Risk
Our market risk disclosures set forth in our Form 10-K for the period ended December 31, 2000, have not changed significantly.
PART II
Item 1. Legal Proceedings
In March 2000, a former investor relations consultant commenced an action in the Supreme Court of the State of New York, New York County, alleging that Titan purportedly breached an agreement dated February 24, 1997, by failing to deliver certain warrants to the plaintiffs. We are vigorously defending the pending action.
Item 6. Exhibits and Reports on Form 8-K
(b) Reports on Form 8-K
There were no current reports on Form 8-K filed for the quarter ended March 31, 2001.
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TITAN PHARMACEUTICALS, INC. | |
| May 15, 2001 | By:
/s/ Louis R. Bucalo
|
| Louis R. Bucalo, M.D. | |
| Chairman, President and Chief Executive Officer | |
| May 15, 2001 | By:
/s/ Robert E. Farrell
|
| Robert E. Farrell | |
| Executive Vice President and Chief Financial Officer |